TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomized, Observer-blind, Controlled, Multi-center Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of One and Two Intramuscular Doses of Influenza Vaccine Versus Control Vaccines in Healthy Subject Aged 6 to <72 Months
Brief Summary: This study will evaluate the efficacy, safety and immunogenicity of one or two 0.25 mL or 0.5 mL intramuscular injections of an adjuvanted influenza vaccine compared with non-influenza and non-adjuvanted influenza control vaccines in subjects 6 to \<72 months of age.


Options:
A: Arm Label: TIV-adj; Type: EXPERIMENTAL; Interventions: Biological: Adjuvanted trivalent inactivated subunit influenza vaccine | Arm Label: Flu-control; Type: ACTIVE_COMPARATOR; Interventions: Biological: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine | Arm Label: Non-flu Control; Type: SHAM_COMPARATOR; Interventions: Biological: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine | Intervention Type: BIOLOGICAL; Name: Adjuvanted trivalent inactivated subunit influenza vaccine; Assigned to Arm(s): TIV-adj | Intervention Type: BIOLOGICAL; Name: Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine; Assigned to Arm(s): Flu-control | Intervention Type: BIOLOGICAL; Name: Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine; Assigned to Arm(s): Non-flu Control
B: Arm Label: Afluria Cohort A; Type: EXPERIMENTAL; Interventions: Biological: CSL's Influenza Virus Vaccine (Afluria) | Arm Label: Afluria Cohort B; Type: EXPERIMENTAL; Interventions: Biological: CSL's Influenza Virus Vaccine (Afluria) | Arm Label: Afluria Cohort C; Type: EXPERIMENTAL; Interventions: Biological: CSL's Influenza Virus Vaccine (Afluria) | Arm Label: Fluzone Cohort A; Type: ACTIVE_COMPARATOR; Interventions: Biological: Influenza Virus Vaccine (Fluzone) | Arm Label: Fluzone Cohort B; Type: ACTIVE_COMPARATOR; Interventions: Biological: Influenza Virus Vaccine (Fluzone) | Arm Label: Fluzone Cohort C; Type: ACTIVE_COMPARATOR; Interventions: Biological: Influenza Virus Vaccine (Fluzone) | Intervention Type: BIOLOGICAL; Name: CSL's Influenza Virus Vaccine (Afluria); Assigned to Arm(s): Afluria Cohort A, Afluria Cohort B, Afluria Cohort C | Intervention Type: BIOLOGICAL; Name: Influenza Virus Vaccine (Fluzone); Assigned to Arm(s): Fluzone Cohort A, Fluzone Cohort B, Fluzone Cohort C
C: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Liquid CAIV-T; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NIMH Multisite HIV/STD Prevention Trial for African American Couples
Brief Summary: This study will evaluate the effectiveness of a risk-reduction program in preventing the transmission of HIV and sexually transmitted diseases among African-American heterosexual couples, with one partner having been previously diagnosed with an HIV infection.


Options:
A: Intervention Type: DEVICE; Name: Ortho All-Flex diaphragm and Replens lubricant gel; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Eban HIV/STD Risk Reduction Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Eban Health Promotion Intervention | Intervention Type: BEHAVIORAL; Name: Eban HIV/STD Risk Reduction Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Eban Health Promotion Intervention; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Community Popular Opinion Leader (C-POL), Behavioral: HIV/STD educational materials | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: HIV/STD educational materials | Intervention Type: BEHAVIORAL; Name: Community Popular Opinion Leader (C-POL); Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: HIV/STD educational materials; Assigned to Arm(s): 1, 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: HORIZONS HIV Intervention | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: enhanced standard-of-care | Intervention Type: BEHAVIORAL; Name: HORIZONS HIV Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: enhanced standard-of-care; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using a Telemedicine System to Promote Patient Care Among Underserved Individuals
Brief Summary: We have established a Telemedicine System for chronic disease management. Based on a personal health record, we have successfully used this system in diverse populations, in over 600 patients, and in multiple disease states (heart failure, CVD risk reduction, gestational diabetes). In this proposal, we will enhance this Telemedicine system to support patient centered care (PCC) by increasing access, incorporating hypertension treatment guideline, quality measures, automating reminders and feedback for both patients and health care providers.

Inner-city, primarily African-American patients (N=252) with uncontrolled hypertension (BP\<140/90 mmHg) and who are followed by primary care physicians will be randomized to either a usual care or a telemedicine group (Telemedicine plus usual care). Blood pressure, weight, BMI, blood glucose and lipids, and physical activity will be measured at baseline and at 6 months. We hypothesize that more subjects in the telemedicine group will achieve goal blood pressure than in the control group. This will occur through increases in knowledge, self-management, shared decision-making, and improved doctor-patient interaction. Primary end- point will be the proportion of subjects who achieve goal blood pressure. Secondary end-points will include:

Rate of self-monitoring, steps per day, weight, CVD knowledge, number of patients at medication guidelines, and increased satisfaction with practice. Telemedicine utilization will also be determined. We believe that telemedicine can facilitate PCC and reduce blood pressure in a cost effective manner.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2
B: Arm Label: access to intermediate care clinics; Type: EXPERIMENTAL; Interventions: Other: intermediate care clinics (ICCs) | Arm Label: usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: intermediate care clinics (ICCs); Assigned to Arm(s): access to intermediate care clinics
C: Arm Label: Behavioral; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker home visits | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Health Worker home visits | Intervention Type: BEHAVIORAL; Name: Community Health Worker home visits; Assigned to Arm(s): Behavioral, Usual Care
D: Arm Label: Advanced care; Type: OTHER; Interventions: Other: Advanced Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Advanced Care; Assigned to Arm(s): Advanced care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using a Telemedicine System to Promote Patient Care Among Underserved Individuals
Brief Summary: We have established a Telemedicine System for chronic disease management. Based on a personal health record, we have successfully used this system in diverse populations, in over 600 patients, and in multiple disease states (heart failure, CVD risk reduction, gestational diabetes). In this proposal, we will enhance this Telemedicine system to support patient centered care (PCC) by increasing access, incorporating hypertension treatment guideline, quality measures, automating reminders and feedback for both patients and health care providers.

Inner-city, primarily African-American patients (N=252) with uncontrolled hypertension (BP\<140/90 mmHg) and who are followed by primary care physicians will be randomized to either a usual care or a telemedicine group (Telemedicine plus usual care). Blood pressure, weight, BMI, blood glucose and lipids, and physical activity will be measured at baseline and at 6 months. We hypothesize that more subjects in the telemedicine group will achieve goal blood pressure than in the control group. This will occur through increases in knowledge, self-management, shared decision-making, and improved doctor-patient interaction. Primary end- point will be the proportion of subjects who achieve goal blood pressure. Secondary end-points will include:

Rate of self-monitoring, steps per day, weight, CVD knowledge, number of patients at medication guidelines, and increased satisfaction with practice. Telemedicine utilization will also be determined. We believe that telemedicine can facilitate PCC and reduce blood pressure in a cost effective manner.


Options:
A: Arm Label: Telemedicine; Type: N/A; Interventions: N/A | Arm Label: Telephone; Type: N/A; Interventions: N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Transtelephonic monitoring (TTM) | Arm Label: Remote; Type: ACTIVE_COMPARATOR; Interventions: Other: Medtronic CareLink® Network | Intervention Type: OTHER; Name: Transtelephonic monitoring (TTM); Assigned to Arm(s): Control | Intervention Type: OTHER; Name: Medtronic CareLink® Network; Assigned to Arm(s): Remote
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Use of PDA + support to reduce weight and pain | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: MOVE! level 2 group weight loss counseling | Intervention Type: BEHAVIORAL; Name: Use of PDA + support to reduce weight and pain; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: MOVE! level 2 group weight loss counseling; Assigned to Arm(s): Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using a Telemedicine System to Promote Patient Care Among Underserved Individuals
Brief Summary: We have established a Telemedicine System for chronic disease management. Based on a personal health record, we have successfully used this system in diverse populations, in over 600 patients, and in multiple disease states (heart failure, CVD risk reduction, gestational diabetes). In this proposal, we will enhance this Telemedicine system to support patient centered care (PCC) by increasing access, incorporating hypertension treatment guideline, quality measures, automating reminders and feedback for both patients and health care providers.

Inner-city, primarily African-American patients (N=252) with uncontrolled hypertension (BP\<140/90 mmHg) and who are followed by primary care physicians will be randomized to either a usual care or a telemedicine group (Telemedicine plus usual care). Blood pressure, weight, BMI, blood glucose and lipids, and physical activity will be measured at baseline and at 6 months. We hypothesize that more subjects in the telemedicine group will achieve goal blood pressure than in the control group. This will occur through increases in knowledge, self-management, shared decision-making, and improved doctor-patient interaction. Primary end- point will be the proportion of subjects who achieve goal blood pressure. Secondary end-points will include:

Rate of self-monitoring, steps per day, weight, CVD knowledge, number of patients at medication guidelines, and increased satisfaction with practice. Telemedicine utilization will also be determined. We believe that telemedicine can facilitate PCC and reduce blood pressure in a cost effective manner.


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: IVR based cognitive behavioral therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Face to face cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: Face to face cognitive behavior therapy; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: IVR based cognitive behavioral therapy; Assigned to Arm(s): Arm 1
B: Arm Label: Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice, Behavioral: Poor weather forecast warning | Arm Label: No Forecast; Type: EXPERIMENTAL; Interventions: Behavioral: COPD self care advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: COPD self care advice; Assigned to Arm(s): Forecast, No Forecast | Intervention Type: BEHAVIORAL; Name: Poor weather forecast warning; Assigned to Arm(s): Forecast
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedicine | Arm Label: 2; Type: NO_INTERVENTION; Interventions: Behavioral: Telemedicine | Intervention Type: BEHAVIORAL; Name: Telemedicine; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: Mammography appointment reminders; telephone counseling; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Single Centre, Randomised Controlled Study of the Effect of NOGA-guided Direct Intramyocardial Injection of Mesenchymal Stromal Cells on the Development of New Myocardium and Blood Vessels in Patients With Heart Failure
Brief Summary: It is a single centre, randomised controlled study of the effect of NOGA-guided direct intramyocardial injection of mesenchymal stromal cells on the development of new myocardium and blood vessels in patients with heart failure.

Stem cells will be obtained from the bone marrow and culture expanded for 6 - 8 weeks before injected into the myocardium.

The patients will be followed with safety, clinical, MRI and CT endpoints for 1 year.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mesenchymal stromal cell | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline | Intervention Type: BIOLOGICAL; Name: Mesenchymal stromal cell; Assigned to Arm(s): 1 | Intervention Type: BIOLOGICAL; Name: Saline; Assigned to Arm(s): 2
B: Arm Label: Treatment Arm; Type: EXPERIMENTAL; Interventions: Biological: Auto-CD34+ cells | Arm Label: Active Control Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo: Diluent used to suspend Auto-CD34+ cells | Arm Label: Unblinded Standard of Care (SOC) Arm; Type: OTHER; Interventions: Other: Standard of care | Intervention Type: BIOLOGICAL; Name: Auto-CD34+ cells; Assigned to Arm(s): Treatment Arm | Intervention Type: BIOLOGICAL; Name: Placebo: Diluent used to suspend Auto-CD34+ cells; Assigned to Arm(s): Active Control Arm | Intervention Type: OTHER; Name: Standard of care; Assigned to Arm(s): Unblinded Standard of Care (SOC) Arm
C: Arm Label: Myocardial infarction; Type: N/A; Interventions: Other: cell therapy | Arm Label: Ischemic cardiomyopathy; Type: N/A; Interventions: Other: cell therapy | Intervention Type: OTHER; Name: cell therapy; Assigned to Arm(s): Ischemic cardiomyopathy, Myocardial infarction
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: C-Cure | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: C-Cure; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis
Brief Summary: Vitamin D likely plays a role in the geography of Multiple Sclerosis (MS), and patients at risk and with MS have relatively low Vitamin D levels compared to their normal counterparts.

This trial examines the safety of high dose oral Vitamin D3 titrated up to a maximum of 40,000 IU per day over a 12 month period. Fifty patients matched for MS and non-MS characteristics will be divided into two groups: one group receiving the high dose Vitamin D regimen, and the other restricted to a maximum of 4000 IU per day. The hypothesis is that patients with MS can tolerate seemingly high doses of Vitamin D3 without adverse events and/or calcium-related abnormalities. It is also hypothesized that those receiving the higher doses will demonstrate improved relapse and disability status compared to controls, and that the treatment group will show improved markers of bone health and immune indicators of reduced inflammation.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
B: Intervention Type: DRUG; Name: Calcium 500 mg/day and vitamin D 700 IU/day; Assigned to Arm(s): N/A
C: Arm Label: Ia; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: Ib; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate and cholecalciferol | Arm Label: IIa; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: IIb; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate and cholecalciferol; Assigned to Arm(s): Ia, Ib
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Ergocalciferol (vitamin D2), Dietary Supplement: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol (vitamin D3), Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Ergocalciferol (vitamin D2); Assigned to Arm(s): 2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol (vitamin D3); Assigned to Arm(s): 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis
Brief Summary: Vitamin D likely plays a role in the geography of Multiple Sclerosis (MS), and patients at risk and with MS have relatively low Vitamin D levels compared to their normal counterparts.

This trial examines the safety of high dose oral Vitamin D3 titrated up to a maximum of 40,000 IU per day over a 12 month period. Fifty patients matched for MS and non-MS characteristics will be divided into two groups: one group receiving the high dose Vitamin D regimen, and the other restricted to a maximum of 4000 IU per day. The hypothesis is that patients with MS can tolerate seemingly high doses of Vitamin D3 without adverse events and/or calcium-related abnormalities. It is also hypothesized that those receiving the higher doses will demonstrate improved relapse and disability status compared to controls, and that the treatment group will show improved markers of bone health and immune indicators of reduced inflammation.


Options:
A: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: cholecalciferol, Dietary Supplement: calcium carbonate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: calcium carbonate; Assigned to Arm(s): 1, 2
C: Arm Label: VigantOL® oil; Type: EXPERIMENTAL; Interventions: Drug: VigantOL oil plus interferon beta-1a (Rebif) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo plus interferon beta-1a (Rebif) | Arm Label: Rebif; Type: EXPERIMENTAL; Interventions: Biological: Interferon beta-1a (Rebif®) alone | Intervention Type: DRUG; Name: VigantOL oil plus interferon beta-1a (Rebif); Assigned to Arm(s): VigantOL® oil | Intervention Type: DRUG; Name: Placebo plus interferon beta-1a (Rebif); Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a (Rebif®) alone; Assigned to Arm(s): Rebif
D: Arm Label: High dose vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Low dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): High dose vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Low dose vitamin D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Dose-Escalation Trial of Vitamin D3 With Calcium Supplementation in Patients With Multiple Sclerosis
Brief Summary: Vitamin D likely plays a role in the geography of Multiple Sclerosis (MS), and patients at risk and with MS have relatively low Vitamin D levels compared to their normal counterparts.

This trial examines the safety of high dose oral Vitamin D3 titrated up to a maximum of 40,000 IU per day over a 12 month period. Fifty patients matched for MS and non-MS characteristics will be divided into two groups: one group receiving the high dose Vitamin D regimen, and the other restricted to a maximum of 4000 IU per day. The hypothesis is that patients with MS can tolerate seemingly high doses of Vitamin D3 without adverse events and/or calcium-related abnormalities. It is also hypothesized that those receiving the higher doses will demonstrate improved relapse and disability status compared to controls, and that the treatment group will show improved markers of bone health and immune indicators of reduced inflammation.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Vitamin D3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Arm Label: Miglyol-oil; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Miglyol-oil
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Control; Type: OTHER; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Control
D: Arm Label: vitamin D3 supplementation; Type: EXPERIMENTAL; Interventions: Drug: A single one ml injection | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: A single one ml injection | Intervention Type: DRUG; Name: A single one ml injection; Assigned to Arm(s): Placebo, vitamin D3 supplementation

Answer: C